Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR STRENGTHENS COLLABORATION WITH TOP 5 GLOBAL PHARMACEUTICAL PARTNER THROUGH ADDITIONAL FORMULATION AGREEMENT
- Eighth new technology partnership with major pharmaceutical and biotech companies since IPO
Cambridge, UK, 14 February 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an additional formulation study agreement with its top five global pharmaceutical partner, building on a collaboration formed in 2022.
Under the terms of this agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop improved, stable, high concentration, liquid formulations of its proprietary product. The partner company will fund the initial development work and have the option to acquire the rights to the new proprietary formulations and associated intellectual property under a technology licensing model. This agreement follows the first agreement with the partner company, announced in June 2022.
Sarah Howell, Chief Executive Officer of Arecor, said: “The expansion of this important collaboration with a leading pharmaceutical company clearly demonstrates Arecor’s expertise and the adaptability of our Arestat™ platform. This is the eighth new technology partnership with major pharmaceutical and biotech companies since Arecor’s IPO in June 2021, which shows the need for our technology among leading pharmaceutical companies developing innovative products.
“This is key to the positive impact we can bring to our partners’ development programmes, not only providing upside potential to Arecor from future licensing opportunities, but also further cementing our reputation within the industry as the go-to partner for challenging and complex formulation expertise.”
Consilium Strategic Communications
Chris Gardner, David Daley, Lindsey Neville Tel: +44 (0) 20 3709 5700